Sanofi India Ltd - SANOFI INDIA Share Price

Sector: Pharmaceuticals | ISIN: INE058A01010
₹ 8,399.35 (-1.25%) icon16 Apr, 2024, 12:00:00 AM

Sanofi India Ltd KEY RATIOS

sector: Pharmaceuticals

  • CMP

    as on 4/16/2024 12:00:00 AM

    ₹ 8399.35 -105.95 -1.25
  • Open
  • ₹ 8,480.6
  • Prev. Close
  • ₹ 8,505.3
  • Turnover(Lac.)
  • ₹ 1,601
  • Day's High
  • ₹ 8,522.85
  • Day's Low
  • ₹ 8,354.8
  • 52 Week's High
  • ₹ 9,380
  • 52 Week's Low
  • ₹ 5,400
  • Book Value
  • ₹ 815.91
  • Face Value
  • ₹ 10
  • Mkt Cap (₹ Cr.)
  • 19,343.7
  • P/E
  • 32.74
  • EPS
  • 256.41
  • Divi. Yield
  • 1.99

Sanofi India Ltd Corporate Actions

23 Feb , 2024

12:00 AM

Dividend

Dividend amount: 50
Announcement date: 23 Feb , 2024

View Details

24 Jan , 2024

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

13 Nov , 2023

12:00 AM

19 Oct , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

19 Oct , 2023

12:00 AM

26 Sep , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

26 Jul , 2023

12:00 AM

26 Jul , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

23 Feb , 2023

12:00 AM

AGM

Announcement date: 23 Feb , 2023

View Details

11 Apr , 2023

12:00 AM

11 Apr , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

23 Feb , 2023

12:00 AM

Dividend

Dividend amount: 194
Announcement date: 23 Feb , 2023

View Details

23 Feb , 2023

12:00 AM

Dividend

Dividend amount: 183
Announcement date: 23 Feb , 2023

View Details

23 Feb , 2023

12:00 AM

BookCloser

View Details

No Record Found


Sanofi India Ltd News and Update

Image not found

In their latest research report, analysts at IIFL Securities highlight prescription volumes and market share trends for the key US products for Indian generic companies.

Image not found

Comparative analysis of India formulations business across players

In their latest report, analysts at IIFL Securities compare the India formulations business of pharma companies, across 14 different parameters, including market share (MS) gains in the domestic pharma market, contribution of volume growth to overall India business growth, among others.

  • 12 Oct, 2022 |
  • 6:21 AM

Invest wise with Expert advice

mobile icon
  • Open Demat with exclusive Advice & Services
  • Get a dedicated Relationship Manager to help you grow your wealth
  • Exclusive advisory on 20+ trading & wealth based investment options
  • One tap Investments, Automated trading & much more
  • Minimum 1 lakh margin required

Sanofi India Ltd SHAREHOLDING SNAPSHOT
17 April , 2024 | 01:19 AM

PROMOTER - TOTAL60.40%

Indian: 0.00%

Foreign: 60.3961%

NON-PROMOTER - TOTAL 39.60%

Institutions: 29.02%

Non-Institutions: 10.58%

CUSTODIES - 0.00%

Custodies: 0.00%

See More Details
ad IconAd Image

Sanofi India Ltd FINANCIALS

No Data Available To Display Chart

Sanofi India Ltd PEER COMPARISON

Figures of Market Capital(Mar Cap), Quaterly Net Profit(NP Qtr) and Quaterly Sales(Sales Qtr) are in ₹ Cr.View All Peer Comparison

MORE ABOUT Sanofi India Ltd

  • Aditya Narayan
  • Chairman & Independent Directo
  • Usha Thorat
  • Independent Director
  • Vaibhav KARANDIKAR
  • Whole Time Director & CFO
  • Rahul Bhatnagar
  • Independent Director
  • Marc-Antoine Lucchini
  • Director
  • Annapurna Das
  • Director
  • Rodolfo Hrosz
  • Managing Director
  • Radhika Shah
  • Company Secretary
  • Renee Amonkar
  • WTD & Additional Director

Summary

Sanofi India Limited, (Previously known as Aventis Pharma Limited), is amongst the leading multinational companies (MNCs) in the Indian Pharmaceutical Market. The Company offers a wide array of medicines for therapy areas such as Diabetes (both insulins, andoral medications), Cardiology, Thrombosis, Epilepsy, Allergies, Infections, Vitamins, Central Nervous System and Antihistamines. The products manufactured by the Company are distributed in India and exported to many developed as well as developing countries, including Germany, Australia, UK, Russia and Italy. Sanofi Indias products viz. Lantus, Combiflam, Amaryl and Allegra feature in the top 100 pharmaceutical brands in India. The Company has its own manufacturing facility at Goa and Ankleshwar, Gujarat. It sells products through independent distributors primarily in India.Sanofi, one of the worlds leading pharmaceutical companies, and its 100% subsidiary, Hoechst GmbH, are the major shareholders of Sanofi India Limited and together hold 60.37% of its paid-up share capital. The Company was incorporated in May 1956 under the name Hoechst Fedco Pharma Private Limited. Over the years, the name was changed to Hoechst Pharmaceuticals Private Limited, Hoechst India Limited, Hoechst Marion Roussel Limited, Aventis Pharma Limited and Sanofi India Limited.During the year 1997-98, the Joint Venture Company, Chiron Behring Vaccines Pvt Ltd started to manufacture anti-rabbies vaccine Rabipur. Roussel India Ltd was amalgamated with... Read More


Reports by Sanofi India Ltd


Reports by Sanofi India Ltd

Company FAQ

No Record Found